Bank of America Rates Iambic Therapeutics Buy
The firm sets a $30 price target on the AI-driven drug developer, citing its lead candidate IAM1363.
Updated on Nov. 9, 2026 in Biotech
Bank of America initiated coverage of Iambic Therapeutics with a buy rating and a $30 price target, implying roughly 194% upside. The firm points to Iambic's AI-based approach to designing drug molecules and to early clinical data for its lead candidate.
Why it matters
The rating places a major bank's endorsement behind an artificial intelligence approach to drug design, a model that depends on advancing candidates through costly clinical trials. Strategic investments from Takeda, AbbVie, Bayer and Revolution Medicines, totaling more than $2 billion, suggest sustained interest from large drugmakers in this approach.
The clinical data covered 53 participants in the IAM1363 study, with tumours shrinking in 19 of them. Bank of America's valuation rests on a 40% probability of success and $1.6 billion in peak sales, assumptions the source does not verify.
The players
Bank of America
A major United States multinational investment bank whose analysts initiated coverage of Iambic with a buy rating.
Iambic Therapeutics
A biotechnology company that uses artificial intelligence to design drug molecules, with IAM1363 as its lead candidate.
Takeda
A Japanese pharmaceutical company that is among the investors that have together committed more than $2 billion to Iambic.
AbbVie
A global biopharmaceutical company that is among the investors that have together committed more than $2 billion to Iambic.
Bayer
A German multinational life sciences company that is among the investors that have together committed more than $2 billion to Iambic.
The details
Iambic applies artificial intelligence directly to designing drug molecules rather than only identifying disease targets. Its lead candidate, IAM1363, targets HER2-driven solid tumours, and Bank of America values the company using a sum-of-the-parts approach.
Timeline
2026: Clinical data for IAM1363 was presented at the European Society for Medical Oncology congress.
Next year: Iambic expects to advance IAM1363 into phase 3 trials.
Fourth quarter of 2028: Post-IPO cash is expected to fund operations.
2029: Bank of America forecasts research and development spending reaching $341 million.
Roadmap
Iambic's investor base, which includes Revolution Medicines alongside Takeda, AbbVie and Bayer, places it among drugmakers funding AI-driven candidate development. The company's path to phase 3 for IAM1363 will test whether that backing translates into late-stage clinical progress.
For readers, the near-term effect is limited to investment decisions, since IAM1363 remains in trials and has no approved use. Any eventual treatment would depend on completing phase 3 testing, a step the company says it expects to begin next year.
The takeaway
Investors weighing AI-driven drug developers should watch whether early response rates hold up as trials grow, since analyst valuations rest heavily on assumed success probabilities. The phase 3 timeline next year will be the first major test of those assumptions.
What happens next
Iambic expects to advance IAM1363 into phase 3 trials next year, and expects post-IPO cash to fund operations into the fourth quarter of 2028.
Further reading
For more on how artificial intelligence is reshaping drug development, explore the Biotech section.
